Overview
Dextroamphetamine is the dextrorotatory (right-handed) enantiomer of amphetamine and the more pharmacologically potent half of the amphetamine molecule. While racemic amphetamine contains equal parts d- and l-amphetamine, the d-enantiomer is approximately 3-4 times more potent at promoting dopamine release, making it the primary driver of amphetamine's therapeutic and recreational effects .
Clinical Significance
Marketed as Dexedrine (immediate-release) and as the major component of Adderall (a mixture of amphetamine salts in a 75:25 d:l ratio for the XR formulation), dextroamphetamine is a first-line medication for ADHD and narcolepsy . It is also the active metabolite of the prodrug lisdexamfetamine (Vyvanse), meaning that three of the most commonly prescribed ADHD medications ultimately rely on the same molecule.
Pharmacological Profile
Like all amphetamines, dextroamphetamine is a full agonist at the trace amine-associated receptor 1 (TAAR1) and a substrate for the dopamine transporter (DAT), norepinephrine transporter (NET), and vesicular monoamine transporter 2 (VMAT2). It promotes the release of dopamine and norepinephrine through reverse transport while simultaneously inhibiting their reuptake . The d-enantiomer's selectivity for dopaminergic over noradrenergic pathways relative to the l-enantiomer is what gives it stronger reinforcing, euphoric, and attention-enhancing properties .
The Enantiomer Difference
The potency ratio between d- and l-amphetamine varies by measure: approximately 4:1 for dopamine release and self-administration behavior, 10:1 for locomotor stimulation, and roughly 2:1 for cardiovascular effects and subjective "high" . The l-enantiomer retains meaningful noradrenergic activity, which is why Adderall includes it — the combination may offer broader symptomatic coverage than pure dextroamphetamine alone.
References
- Heal DJ et al. "Amphetamine, past and present — a pharmacological and clinical perspective." J Psychopharmacol. 2013;27(6):479-496.
- FDA. Dexedrine prescribing information.
- NCBI Bookshelf. "Amphetamine." StatPearls. 2024.
- Taylor KM, Snyder SH. "Amphetamine: Differentiation by d and l isomers of behavior involving brain norepinephrine or dopamine." Science. 1970;168(3938):1487-1489.
Safety at a Glance
High Risk- General Principles
- Start low, go slow: Always begin with a low dose, especially with unfamiliar batches or new substances. Individual se...
- Toxicity: Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and ...
- Dangerous with: Atropa belladonna, Datura, Diphenhydramine, Harmala alkaloid, 25x-NBOMe, 2C-T-x, DOx (+2 more)
- Overdose risk: Stimulant overdose from Dextroamphetamine is a medical emergency primarily involving cardiovascul...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
insufflated
oral
Duration
insufflated
Total: 3 hrs – 6 hrsoral
Total: 6 hrs – 8 hrsHow It Feels
The onset of oral dextroamphetamine is a study in clean pharmacological efficiency. Within thirty to forty-five minutes, a crystalline clarity descends upon the mind. The usual fog of competing thoughts and stalled intentions lifts, and in its place there is a focused, orderly wakefulness that feels earned rather than imposed. Energy builds steadily, not as a rush but as a rising tide. There is a subtle euphoria, a brightness to the mood that makes even mundane tasks feel purposeful and the world seem slightly more worth engaging with.
As the effects reach full expression over the next hour, dextroamphetamine delivers what many consider the archetype of the clean stimulant experience. Focus is sharp and sustained, locking onto tasks with an effortless tenacity. Motivation is markedly enhanced, and the resistance to beginning difficult or tedious work nearly vanishes. Conversation flows with unusual fluency and confidence. Physical energy is elevated but controlled, more endurance than frenzy. The body feels light and capable. Appetite disappears completely, the mouth dries, and there is a mild but perceptible increase in heart rate. The jaw may tighten, and there is a characteristic narrowing of attention that serves productivity at the expense of peripheral awareness.
At the peak, typically two to four hours in, the euphoria is genuine but measured. It is the quiet satisfaction of effortless competence rather than the electric ecstasy of a dopamine flood. Social interaction feels natural and rewarding, though there is a tendency to become absorbed in whatever task is at hand. Physical side effects are proportional: elevated heart rate, peripheral vasoconstriction, suppressed appetite, and a restless energy that favors activity. At higher doses, the euphoria becomes more pronounced and the focus can narrow into an obsessive fixation that feels productive in the moment but may not be.
The descent from dextroamphetamine is gradual, spanning four to six hours as the focused clarity slowly returns to baseline. There is a noticeable rebound as the drug clears: energy drops, motivation contracts, and a heavy, slightly irritable fatigue settles in. Appetite returns with force. The crash is real but manageable, lacking the devastating quality of shorter-acting or more potent stimulants. Sleep, while somewhat delayed, arrives without major difficulty. The following day may carry a slight flatness, a reminder that the previous day's exceptional clarity was borrowed rather than generated.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(11)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
- Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Muscle tension— Persistent partial contractions or tightening of muscles that produces uncomfortable stiffness, cram...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Cognitive & Perceptual Effects
Cognitive(9)
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Panic attack— A panic attack is a discrete episode of acute, overwhelming fear or terror that arises suddenly and ...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Pharmacology
TAAR1-Mediated Dopamine Release
Dextroamphetamine's primary mechanism is the promotion of monoamine release through a multi-step intracellular cascade initiated by the trace amine-associated receptor 1 (TAAR1). As a small lipophilic molecule, dextroamphetamine crosses the cell membrane and is also taken up by DAT as a substrate. Once intracellular, it binds to TAAR1 — a G-protein-coupled receptor with predominantly intracellular localization — which activates protein kinase A (PKA) and protein kinase C (PKC) . These kinases phosphorylate the dopamine transporter, triggering two consequences: DAT internalization (reducing dopamine reuptake capacity) and DAT reversal (causing the transporter to pump dopamine out of the cell into the synapse). Simultaneously, dextroamphetamine inhibits vesicular monoamine transporter 2 (VMAT2), releasing stored dopamine from synaptic vesicles into the cytoplasm where it becomes available for reverse transport .
The d/l Potency Difference Explained
Dextroamphetamine's greater potency relative to levoamphetamine at dopamine release stems from higher affinity for DAT and TAAR1-mediated signaling pathways in the mesolimbic dopamine system . In self-administration studies — a proxy for rewarding/addictive potential — d-amphetamine is approximately four times more potent than l-amphetamine. For locomotor stimulation, the ratio widens to roughly 10:1. However, both enantiomers are approximately equipotent at inhibiting norepinephrine uptake in brain catecholamine neurons, explaining why l-amphetamine retains clinically useful noradrenergic effects even while lacking d-amphetamine's dopaminergic punch .
Downstream Effects and Regional Selectivity
Dextroamphetamine preferentially elevates dopamine in the nucleus accumbens and prefrontal cortex — regions critical for reward processing and executive function, respectively. At therapeutic doses (5-30 mg), dopamine elevation in the prefrontal cortex enhances working memory, sustained attention, and cognitive flexibility. Higher doses produce progressively more dopamine release in the nucleus accumbens, shifting the effect profile from cognitive enhancement toward euphoria and reinforcement .
References
- Miller GM. "Amphetamines signal through intracellular TAAR1 receptors coupled to Galpha-13 and Galpha-s." Mol Psychiatry. 2011;16(9):961-972.
- Fleckenstein AE et al. "A receptor mechanism for methamphetamine action in dopamine transporter regulation." J Pharmacol Exp Ther. 2009;330(1):316-325.
- NCBI Bookshelf. "Amphetamine." StatPearls. 2024.
- Taylor KM, Snyder SH. "Amphetamine: Differentiation by d and l isomers." Science. 1970;168(3938):1487-1489.
Detection Methods
Standard Drug Panel Inclusion
Dextroamphetamine is a Schedule II controlled substance that is detected on standard 5-panel immunoassay drug screens. It is the prototypical target of the amphetamine immunoassay channel. All standard workplace (SAMHSA/DOT), clinical, and forensic drug testing panels include amphetamines as a primary analyte. The standard screening cutoff for amphetamines in urine is 500 ng/mL (immunoassay) with a confirmation cutoff of 250 ng/mL (GC-MS/LC-MS/MS).
Urine Detection
Dextroamphetamine is detectable in urine for approximately 2 to 4 days after a single therapeutic dose, and up to 5 to 7 days after heavy or chronic use. Urinary pH significantly affects the detection window: acidic urine (pH below 6.0) accelerates renal excretion and shortens the detection window, while alkaline urine (pH above 7.5) promotes tubular reabsorption and extends it. Approximately 30 to 40 percent of the dose is excreted unchanged in urine, with the remainder undergoing hepatic metabolism via deamination, hydroxylation, and conjugation.
Blood and Saliva Detection
Dextroamphetamine is detectable in blood for approximately 24 to 48 hours after the last dose. Oral fluid testing can detect dextroamphetamine for 24 to 50 hours, and saliva-based testing is increasingly used in roadside and workplace settings. The oral fluid screening cutoff is typically 25 ng/mL.
Hair Follicle Detection
Hair follicle testing can detect dextroamphetamine for up to 90 days (standard 1.5-inch sample). Amphetamines incorporate well into hair and are included on all standard hair testing panels. The SAMHSA-recommended screening cutoff for amphetamines in hair is 500 pg/mg, with a confirmation cutoff of 300 pg/mg.
Confirmatory Testing
GC-MS and LC-MS/MS are used to confirm positive immunoassay results. Chiral analysis can distinguish dextroamphetamine (d-amphetamine) from levoamphetamine (l-amphetamine), which is relevant for differentiating prescribed use from illicit methamphetamine use (which produces both isomers as metabolites). This distinction is important in medical review officer (MRO) interpretation of positive results.
Reagent Testing
Marquis reagent produces an orange to reddish-brown color with dextroamphetamine, consistent with the primary amine amphetamine reaction. Simon's reagent produces no color change (negative for secondary amines), distinguishing amphetamine from methamphetamine. Mandelin reagent produces a green to dark green color. These reactions are consistent and well-characterized for pharmaceutical-grade dextroamphetamine.
Interactions
| Substance | Status | Note |
|---|---|---|
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 25x-NBOMe | Unsafe | — |
| 2C-T-x | Unsafe | — |
| DOx | Unsafe | — |
| PCP | Unsafe | — |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 25E-NBOH | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-2 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-21 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Alcohol | Uncertain | — |
| Caffeine | Uncertain | — |
| Cannabis | Uncertain | — |
| Cocaine | Uncertain | — |
| GBL | Uncertain | — |
History
Dexedrine: Isolating the Active Enantiomer
While racemic amphetamine (Benzedrine) had been available since 1933, pharmacologists recognized early on that the two enantiomers had different potency profiles. Smith, Kline & French introduced dextroamphetamine as Dexedrine in 1937, marketing it as a more potent and refined stimulant than racemic Benzedrine. By 1945, Dexedrine civilian sales were already substantial, reaching $650,000 — a significant sum for a single drug formulation at the time .
Military Applications
Dextroamphetamine became a standard-issue military performance enhancer during World War II and beyond. It was the preferred variant for Air Force pilots during the Korean and Vietnam wars and continued to be used (as "go pills") in the U.S. military through the Gulf War era. The Air Force officially authorized dextroamphetamine for long-duration bombing missions as late as 2002, a policy that generated significant public controversy .
Adderall and the Modern Era
In 1996, the pharmaceutical company Richwood introduced Adderall, a formulation combining four amphetamine salts: dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate. The resulting 3:1 d:l ratio (75:25 in Adderall XR) was designed to provide predominantly dopaminergic effects from dextroamphetamine while retaining the noradrenergic contributions of levoamphetamine . Adderall rapidly became the most prescribed amphetamine formulation for ADHD in the United States and remains so today.
References
- Rasmussen N. "America's first amphetamine epidemic 1929-1971." Am J Public Health. 2008;98(6):974-985.
- Caldwell JA, Caldwell JL. "Fatigue in military aviation: an overview of U.S. military-approved pharmacological countermeasures." Aviat Space Environ Med. 2005;76(7 Suppl):C39-51.
- Heal DJ et al. "Amphetamine, past and present — a pharmacological and clinical perspective." J Psychopharmacol. 2013;27(6):479-496.
Harm Reduction
General Principles
- Start low, go slow: Always begin with a low dose, especially with unfamiliar batches or new substances. Individual sensitivity varies enormously.
- Test your substances: Use reagent test kits to verify identity and check for dangerous adulterants. Consider using drug checking services where available.
- Research thoroughly: Understand expected dose ranges, duration, potential interactions, and contraindications before use.
- Never use alone: Have a trusted, sober person present, especially with new substances or higher doses.
- Set and setting: Your mindset and environment profoundly influence the experience. Choose a safe, comfortable environment and ensure you're in a stable psychological state.
Dextroamphetamine-Specific Harm Reduction
- Cardiovascular monitoring: Stimulants increase heart rate and blood pressure. Avoid strenuous physical activity and stay hydrated. Those with heart conditions should not use stimulants.
- Hydration and nutrition: Eat before and during use, even if appetite is suppressed. Set reminders to drink water regularly but avoid overhydration.
- Sleep: Do not redose to avoid the comedown. Set a firm cutoff time to allow adequate sleep. Sleep deprivation amplifies negative effects and health risks.
- Compulsive redosing: Many stimulants produce a strong urge to redose. Pre-measure your dose and commit to it. Remove access to additional substance if possible.
- Dental health: Bruxism (jaw clenching) can damage teeth. Use magnesium supplements and consider a mouth guard for longer sessions.
- Combination danger: Never combine with MAOIs — this can cause hypertensive crisis. Combining with other stimulants compounds cardiovascular risk.
Toxicity & Safety
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
Alcohol - Drinking alcohol on stimulants is considered risky because it reduces the sedative effects of the alcohol that the body uses to gauge drunkenness. This often leads to excessive drinking with greatly reduced inhibitions, increasing the risk of liver damage and increased dehydration. The effects of stimulants will also allow one to drink past a point where they might normally pass out, increasing the risk. If you do decide to do this then you should set a limit of how much you will drink each hour and stick to it, bearing in mind that you will feel the alcohol and the stimulant less.
GHB/GBL - Stimulants increase respiration rate allowing a higher dose of sedatives. If the stimulant wears off first then the depressant effects of the GHB/GBL may overcome the user and cause respiratory arrest.
Opioids - Stimulants increase respiration rate allowing a higher dose of opiates. If the stimulant wears off first then the opiate may overcome the patient and cause respiratory arrest.
Cocaine - The rewarding effects of cocaine are mediated by DAT inhibition, and an increase of exocytosis of dopamine through the cell membrane. Amphetamine reverses the direction of DAT and the direction vesicular transports within the cell by a pH mediated mechanism of displacement, thus excludes the regular mechanism of dopamine release through means of exocytosis because the effects Na+/K+ ATPase are inhibited. You will find cardiac effects with the combination of cocaine and amphetamine due to a SERT mediated mechanism from the subsequent activation of 5-HT2B, which is an effect of serotonin-related valvulopathy. Amphetamines generally cause hypertension in models of abuse, and this combination can increase the chances of syncope due to turbulent blood flow during valve operation. The rewarding mechanisms of cocaine are reversed by administration of amphetamine.
Cannabis - Stimulants increase anxiety levels and the risk of thought loops and paranoia which can lead to negative experiences.
Caffeine - This combination of stimulants is generally considered unnecessary and may increase strain on the heart, as well as potentially causing anxiety and physical discomfort.
Tramadol - Tramadol and stimulants both increase the risk of seizures.
DXM - Both substances raise heart rate, in extreme cases, panic attacks caused by these substances have led to more serious heart issues.
Ketamine - Combining amphetamine and ketamine may result in psychoses that resemble schizophrenia, but not worse than the psychoses produced by either substance alone, but this is debatable. This is due to amphetamines ability to attenuated the disruption of working memory caused by ketamine. Amphetamine alone may result in grandiosity, paranoia, or somatic delusions with little to no effect on negative symptoms. Ketamine, however, will result in thought disorders, disruption of executive functioning, and delusions due to a modification of conception. These mechanisms are due to an increase of dopaminergic activity in the mesolimbic pathway caused by amphetamine due to its pharmacology effecting dopamine, and due to a disruption of dopaminergic functioning in the mesocortical pathways via NMDA antagonism effects of ketamine. Combining the two, you may expect mainly thought disorder along with positive symptoms.
PCP - Increases risk of tachycardia, hypertension, and manic states.
Methoxetamine - Increases risk of tachycardia, hypertension, and manic states.
Psychedelics (e.g. LSD, mescaline, psilocybin) - Increases risk of anxiety, paranoia, and thought loops.
25x-NBOMe - Amphetamines and NBOMes both provide considerable stimulation that when combined they can result in tachycardia, hypertension, vasoconstriction and, in extreme cases, heart failure. The anxiogenic and focusing effects of stimulants are also not good in combination with psychedelics as they can lead to unpleasant thought loops. NBOMes are known to cause seizures and stimulants can increase this risk.
2C-T-x - Suspected of mild MAOI properties. May increase the risk of hypertensive crisis.
5-MeO-xxT - Suspected of mild MAOI properties. May increase the risk of hypertensive crisis.
aMT - aMT has MAOI properties which may interact unfavorably with amphetamines.
MAOIs - MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably. MAO-A inhibitors with amphetamine can lead to hypertensive crises.
Overdose Information
Stimulant overdose from Dextroamphetamine is a medical emergency primarily involving cardiovascular and neurological toxicity.
Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.
Emergency response:
- Call emergency services immediately
- Keep the person cool (remove excess clothing, apply cool water)
- If seizures occur, protect the head and clear the area of hard objects
- If the person loses consciousness, place in recovery position
- Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionals
Prevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | Develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Internationally, amphetamine (and its isomers dextroamphetamine and levoamphetamine) are Schedule II controlled substances under the United Nations 1971 Convention on Psychotropic Substances.
Australia: Dextroamphetamine is a Schedule 8 controlled substance.
Austria: Dextroamphetamine is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).
Brazil: Dextroamphetamine is a Class A3 psychoactice substance.
Canada: Dextroamphetamine is a Schedule I drug in Canada.
France: Dextroamphetamine is scheduled as a "stupéfiant", i.e. a recognized drug of abuse, as an isomer of amphetamine. It is illegal to possess, buy, sell or manufacture. It is not prescriptible
Germany: Dextroamphetamine is controlled under Anlage III BtMG (Narcotics Act, Schedule III). It can only be prescribed on a narcotic prescription form.
The Netherlands: Dextroamphetamine is a List I controlled substance.
South Korea: Dextromphetamine is prohibited even for medical use in South Korea in compliance with the United Nations Convention on Psychotropic Substances.
Sweden: Dextroamphetamine is a List II controlled substance. It can only be prescribed by doctors with specialist competence in child and adolescent psychiatry, psychiatry, forensic psychiatry, neurology or child and adolescent neurology with habilitation.
United Kingdom: Amphetamine is a Class B drug in the United Kingdom, without any clarification about isomers.
United States: Amphetamine is a Schedule IIN controlled substance in the United States, citing severaldextroamphetamine prescription drugs as examples.
Responsible use
Stimulant
Amphetamine
Enantiomers
Levoamphetamine
Amphetamines
Dextroamphetamine (Wikipedia)
Dextroamphetamine (Erowid Vault)
Dextroamphetamine (DrugBank)
Dextroamphetamine (Drugs.com)
Experience Reports (1)
Tips (7)
Do not combine Dextroamphetamine with MAOIs or other serotonergic drugs. Many stimulants have serotonergic activity, and combinations can cause serotonin syndrome or hypertensive crisis, both medical emergencies.
Start low with Dextroamphetamine and wait for full onset before redosing. Stimulant redosing extends duration and side effects more than it extends euphoria, while adding cardiovascular strain. Set a firm limit before you start.
Test Dextroamphetamine with appropriate reagent kits and fentanyl test strips. Stimulant supplies have increasingly been found contaminated with fentanyl, which has caused a surge in overdose deaths among stimulant users.
If you want to reduce or stop dextroamphetamine use, taper gradually rather than stopping cold turkey. While amphetamine withdrawal isn't physically dangerous like benzo withdrawal, abrupt cessation after regular use can cause severe fatigue, depression, and hypersomnia that lasts days to weeks.
Have a landing plan for the Dextroamphetamine comedown. Prepare food, melatonin or magnesium, and a comfortable environment in advance. Avoid using depressants to manage the comedown as this creates polydrug dependency patterns.
Dextroamphetamine (Dexedrine) is a prescription stimulant primarily used for ADHD. At therapeutic doses (5-20mg), it increases focus and motivation. If you're prescribed it, finding the right dose with your doctor is key — too much causes anxiety and restlessness, too little doesn't adequately manage symptoms.
Community Discussions (2)
See Also
References (4)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- PubChem: Dextroamphetamine
PubChem compound page for Dextroamphetamine (CID: 5826)
pubchem - Dextroamphetamine - TripSit Factsheet
TripSit factsheet for Dextroamphetamine
tripsit - Dextroamphetamine - Wikipedia
Wikipedia article on Dextroamphetamine
wikipedia